Avia Pharma

Avia Pharma, established in 2016 by senior executives from the pharmaceutical and pharmacy industry, operates as a pharmaceutical sales and marketing company with a strong presence in Northern Europe. Co-founders Jacob Calmvik and Jostein Lønberg have guided the company's growth, with Calmvik serving as CEO after a six-year tenure at Apotek Hjärtat in roles including Business Development Director and E-commerce Director. The firm is headquartered in Stockholm, Sweden, with additional offices in Helsinki and Munich.

The company's business model centers on a two-pronged growth strategy: organic expansion and strategic acquisitions. It focuses on both in-licensing established and new medicinal products and acquiring product portfolios. This approach involves forming partnerships with international research, biotech, and pharmaceutical companies to introduce, develop, or revitalize their products in the Nordic and German markets. A significant portion of sales is derived from its own product portfolio, which now exceeds 30 products. Avia Pharma's revenue stream is built upon the sale of prescription (Rx) and over-the-counter (OTC) pharmaceuticals, medical devices, cosmetics, and food supplements. The company has demonstrated substantial growth, surpassing €40 million in sales in 2022.

Operating within the health sector, Avia Pharma targets several key therapeutic areas: dermatology, allergy, women's health, urology, and general OTC products. Its product offerings cater to a wide range of patient needs, from treating conditions like erectile dysfunction and osteoporosis to providing skincare and allergy relief. A key milestone was the January 2024 partnership with Impilo, a Nordic investment company, which became a new majority owner to support Avia's ambition of building a leading Northern European platform. Shortly after, Avia acquired Neubourg Skin Care GmbH, a German dermatology company known for its foam-based foot care brand, Allpresan, significantly strengthening its dermatology portfolio in the German market.

Keywords: pharmaceutical distribution, OTC products, prescription drugs, European pharma, dermatology, women's health, urology, allergy medication, pharmaceutical sales, pharmaceutical marketing, product in-licensing, pharma acquisitions, healthcare investment, Nordic healthcare market, German healthcare market, Jacob Calmvik, Impilo, Neubourg Skin Care, Allpresan, foot care, skin care products, medical devices, food supplements, biotech partnerships